ICON plc, a global clinical research organization, has projected financial targets for the year ending December 31, 2024. The company anticipates full-year revenue to fall between $8.4 and $8.8 billion, representing growth between 3.2% to 8.1%. In addition, adjusted earnings per share are expected to be within the range of $14.50 to $15.30, marking a growth of 13.5% to 19.8% over the midpoint guidance for 2023.
CEO Dr. Steve Cutler noted ICON’s continued market leadership and emphasis on operational efficiency and customer service. The company intends to drive clinical trial efficiencies through investment in tools such as automation and patient and site participation initiatives. Despite economic challenges, the forecast for 2024 reflects a positive demand across ICON’s service segments.
Furthermore, the guidance for Full Year 2023 has been reaffirmed, with revenue anticipated between $8.07 and $8.21 billion and adjusted earnings per share between $12.63 and $12.91. The provided adjusted earnings per share forecasts for both 2023 and 2024 are non-GAAP measures due to uncertainties in predicting certain GAAP measure items with reasonable certainty.
Source link: http://www.businesswire.com/news/home/20240109333358/en/ICON-Issues-Financial-Guidance-for-Full-Year-2024
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.
